BLIMP1 PROTAC

BLIMP1 PROTAC is an experimental proteolysis-targeting chimera designed to induce selective degradation of the transcription factor B-lymphocyte-induced maturation protein 1 (Blimp-1, encoded by PRDM1), a master regulator of plasma cell differentiation and survival in multiple myeloma and other B‑cell malignancies.[4][14] As a heterobifunctional small molecule, it links a ligand that binds BLIMP1 to a ligand recruiting an E3 ubiquitin ligase via a chemical linker, thereby promoting ubiquitination and proteasomal degradation of BLIMP1 rather than simple inhibition.[2][3] In preclinical models, BLIMP1 PROTACs potently and selectively degrade BLIMP1 protein, disrupt BLIMP1‑dependent transcriptional programs, and achieve ≥50% growth inhibition in a substantial subset of multiple myeloma cell lines, including models resistant to standard agents, with associated G1 cell-cycle arrest and apoptosis, highlighting their potential as targeted therapies for BLIMP1‑addicted myeloma.[4][14]